Stock PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
1.83 USD +3.98% Intraday chart for Pacific Biosciences of California, Inc. +24.49% -81.35%
04-22 JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
04-18 Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight
MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating
MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7
MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating
MT
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating
MT
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating
MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating
MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating
MT
UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13
MT
Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating
MT
Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14
MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating
MT
Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating
MT
Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target
MT
UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating
MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating
MT
Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target
MT
Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating
MT
Barclays Initiates Pacific Biosciences of California at Equalweight With $14 Price Target
MT
Morgan Stanley Raises Pacific Biosciences of California's Price Target to $12 From $10, Maintains Equalweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PACB Stock
  4. News Pacific Biosciences of California, Inc.
  5. Analyst Reco.